GLP-1 Receptor Agonists in Metabolic Disease Research

GLP-1 is derived from proglucagon by tissue-specific post-translational processing in intestinal L-cells. It is released within minutes of nutrient ingestion and acts on GLP-1 receptors (GLP-1R) expressed in pancreatic beta cells, the hypothalamus, brainstem, heart, kidney, and peripheral tissues.

The incretin effect — the augmentation of insulin secretion by gut-derived hormones — accounts for 50–70% of postprandial insulin release in healthy individuals. GLP-1 contributes to this effect through glucose-dependent stimulation of insulin secretion, meaning it only potentiates insulin release when blood glucose is elevated, reducing the risk of hypoglycemia.

Semaglutide is a GLP-1 analog with 94% sequence homology to native GLP-1, modified with a C18 fatty diacid chain attached via a linker to lysine at position 26. This modification enables albumin binding, extending the half-life to approximately 7 days and enabling once-weekly dosing in clinical applications.

In preclinical research, semaglutide has been used extensively to study the mechanisms of GLP-1R-mediated weight loss, which involves both peripheral effects (delayed gastric emptying, reduced intestinal motility) and central effects (hypothalamic appetite suppression via arcuate nucleus GLP-1R signaling). Rodent studies using semaglutide have demonstrated 15–20% reductions in body weight, primarily through fat mass reduction.

GLP-1 receptors in the arcuate nucleus of the hypothalamus co-localize with POMC/CART neurons that promote satiety and AgRP/NPY neurons that drive hunger. GLP-1R activation in the arcuate nucleus suppresses AgRP/NPY activity and potentiates POMC signaling, reducing food intake through a central mechanism independent of peripheral glucose effects.

Müller et al. (2022) demonstrated that central GLP-1R signaling is required for the full anorectic effect of semaglutide in mice, as intracerebroventricular GLP-1R antagonism partially attenuated the weight loss observed with peripheral semaglutide administration.

Beyond glycemic and weight effects, GLP-1R agonists have demonstrated cardioprotective and renoprotective effects in preclinical models. GLP-1R activation reduces cardiac ischemia-reperfusion injury in rodent models, an effect attributed to cAMP-mediated cardioprotective signaling. In the kidney, GLP-1R agonists reduce glomerular hyperfiltration and albuminuria in diabetic nephropathy models.

These pleiotropic effects have made GLP-1R agonists valuable research tools for studying the intersection of metabolic, cardiovascular, and renal disease pathways.